[English] 日本語
Yorodumi
- PDB-8f4v: Alpha7 nicotinic acetylcholine receptor intracellular and transme... -

+
Open data


ID or keywords:

Loading...

-
Basic information

Entry
Database: PDB / ID: 8f4v
TitleAlpha7 nicotinic acetylcholine receptor intracellular and transmembrane domains bound to ivermectin in a desensitized state
ComponentsNeuronal acetylcholine receptor subunit alpha-7
KeywordsMEMBRANE PROTEIN / nicotinic acetylcholine receptor / transmembrane and intracellular domain / desensitized state / ivermectin
Function / homology
Function and homology information


sensory processing / synaptic transmission involved in micturition / dendrite arborization / response to acetylcholine / Highly calcium permeable postsynaptic nicotinic acetylcholine receptors / acetylcholine receptor activity / acetylcholine-gated channel complex / regulation of amyloid fibril formation / acetylcholine-gated monoatomic cation-selective channel activity / short-term memory ...sensory processing / synaptic transmission involved in micturition / dendrite arborization / response to acetylcholine / Highly calcium permeable postsynaptic nicotinic acetylcholine receptors / acetylcholine receptor activity / acetylcholine-gated channel complex / regulation of amyloid fibril formation / acetylcholine-gated monoatomic cation-selective channel activity / short-term memory / cation channel complex / dendritic spine organization / chloride channel regulator activity / acetylcholine binding / regulation of amyloid precursor protein catabolic process / acetylcholine receptor signaling pathway / neurotransmitter receptor complex / positive regulation of amyloid-beta formation / negative regulation of amyloid-beta formation / positive regulation of protein metabolic process / response to amyloid-beta / monoatomic ion channel activity / ligand-gated ion channel signaling pathway / modulation of excitatory postsynaptic potential / plasma membrane raft / negative regulation of tumor necrosis factor production / positive regulation of excitatory postsynaptic potential / toxic substance binding / monoatomic ion transport / negative regulation of canonical NF-kappaB signal transduction / negative regulation of cytokine production involved in inflammatory response / positive regulation of long-term synaptic potentiation / excitatory postsynaptic potential / regulation of membrane potential / response to nicotine / synapse organization / calcium channel activity / memory / cognition / intracellular calcium ion homeostasis / positive regulation of angiogenesis / calcium ion transport / transmembrane signaling receptor activity / amyloid-beta binding / monoatomic ion transmembrane transport / chemical synaptic transmission / postsynaptic membrane / learning or memory / response to hypoxia / neuron projection / positive regulation of ERK1 and ERK2 cascade / postsynapse / positive regulation of MAPK cascade / positive regulation of cell population proliferation / dendrite / synapse / endoplasmic reticulum membrane / signal transduction / protein homodimerization activity / membrane / plasma membrane
Similarity search - Function
Nicotinic acetylcholine receptor / Neurotransmitter-gated ion-channel, conserved site / Neurotransmitter-gated ion-channels signature. / Neurotransmitter-gated ion-channel transmembrane domain / Neurotransmitter-gated ion-channel transmembrane region / Neurotransmitter-gated ion-channel transmembrane domain superfamily / Neuronal acetylcholine receptor / Neurotransmitter-gated ion-channel / Neurotransmitter-gated ion-channel ligand-binding domain / Neurotransmitter-gated ion-channel ligand-binding domain superfamily / Neurotransmitter-gated ion-channel ligand binding domain
Similarity search - Domain/homology
Chem-IVM / Neuronal acetylcholine receptor subunit alpha-7
Similarity search - Component
Biological speciesHomo sapiens (human)
MethodSOLUTION NMR / na
AuthorsBondarenko, V. / Chen, Q. / Tang, P.
Funding support United States, 3items
OrganizationGrant numberCountry
National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA)R01DA046939 United States
National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA)T32GM075770 United States
National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA)T32EB009403 United States
CitationJournal: Acs Chem Neurosci / Year: 2023
Title: Structural Elucidation of Ivermectin Binding to alpha 7nAChR and the Induced Channel Desensitization.
Authors: Bondarenko, V. / Chen, Q. / Singewald, K. / Haloi, N. / Tillman, T.S. / Howard, R.J. / Lindahl, E. / Xu, Y. / Tang, P.
History
DepositionNov 11, 2022Deposition site: RCSB / Processing site: RCSB
Revision 1.0Feb 22, 2023Provider: repository / Type: Initial release
Revision 1.1Mar 8, 2023Group: Database references / Category: citation / citation_author
Item: _citation.pdbx_database_id_PubMed / _citation.title ..._citation.pdbx_database_id_PubMed / _citation.title / _citation_author.identifier_ORCID / _citation_author.name
Revision 1.2Mar 29, 2023Group: Database references / Category: citation
Item: _citation.journal_volume / _citation.page_first / _citation.page_last
Revision 1.3May 15, 2024Group: Data collection / Database references / Category: chem_comp_atom / chem_comp_bond / database_2 / Item: _database_2.pdbx_DOI

-
Structure visualization

Structure viewerMolecule:
MolmilJmol/JSmol

Downloads & links

-
Assembly

Deposited unit
A: Neuronal acetylcholine receptor subunit alpha-7
B: Neuronal acetylcholine receptor subunit alpha-7
C: Neuronal acetylcholine receptor subunit alpha-7
D: Neuronal acetylcholine receptor subunit alpha-7
E: Neuronal acetylcholine receptor subunit alpha-7
hetero molecules


Theoretical massNumber of molelcules
Total (without water)153,53410
Polymers149,1595
Non-polymers4,3755
Water00
1


  • Idetical with deposited unit
  • defined by author
  • Evidence: NMR Distance Restraints
TypeNameSymmetry operationNumber
identity operation1_5551
Buried area21370 Å2
ΔGint-157 kcal/mol
Surface area80780 Å2
NMR ensembles
DataCriteria
Number of conformers (submitted / calculated)15 / 1000structures with the lowest energy
RepresentativeModel #1lowest energy

-
Components

#1: Protein
Neuronal acetylcholine receptor subunit alpha-7


Mass: 29831.779 Da / Num. of mol.: 5
Fragment: Transmembrane domain and intracellular domain residues 231-496
Mutation: A263S, V268S, L270S, A474E
Source method: isolated from a genetically manipulated source
Source: (gene. exp.) Homo sapiens (human) / Gene: CHRNA7, NACHRA7 / Plasmid: pTBSG1-TMD+ICD / Cell (production host): E. coli / Production host: Escherichia coli (E. coli) / Strain (production host): Rosetta 2(DE3) pLysS / References: UniProt: P36544
#2: Chemical
ChemComp-IVM / (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17 -oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacy clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside / 22,23-DIHYDROAVERMECTIN B1A / IVERMECTIN


Mass: 875.093 Da / Num. of mol.: 5 / Source method: obtained synthetically / Formula: C48H74O14 / Feature type: SUBJECT OF INVESTIGATION / Comment: antiparasitic*YM
Has ligand of interestY

-
Experimental details

-
Experiment

ExperimentMethod: SOLUTION NMR
NMR experiment
Conditions-IDExperiment-IDSolution-IDSample stateSpectrometer-IDType
111isotropic12D 1H-15N TROSY-HSQC
122isotropic12D 1H-15N TROSY-HSQC
133isotropic12D 1H-15N TROSY-HSQC
144isotropic12D 1H-15N TROSY-HSQC
155isotropic12D 1H-15N TROSY-HSQC
166isotropic12D 1H-15N STD TROSY-HSQC
177isotropic12D 1H-15N STD TROSY-HSQC
188isotropic12D 1H-15N STD TROSY-HSQC
199isotropic12D NOESY
11010isotropic12D 1H-15N TROSY-HSQC
11111isotropic12D 1H-15N TROSY-HSQC
11212isotropic12D 1H-15N TROSY-HSQC
11313isotropic12D 1H-15N TROSY-HSQC
11414isotropic12D 1H-15N TROSY-HSQC
11515isotropic12D 1H-15N TROSY-HSQC
11616isotropic12D 1H-15N TROSY-HSQC
11717isotropic12D 1H-15N TROSY-HSQC
11818isotropic12D 1H-15N TROSY-HSQC
11919isotropic12D 1H-15N TROSY-HSQC
12020isotropic12D 1H-15N TROSY-HSQC
12121isotropic12D 1H-15N TROSY-HSQC
12222isotropic12D 1H-15N TROSY-HSQC
12323isotropic12D 1H-15N TROSY-HSQC
12424isotropic12D 1H-15N TROSY-HSQC
12525isotropic12D 1H-15N TROSY-HSQC
12626isotropic13D TROSY-HNCO
12727isotropic13D TROSY-HNCO

-
Sample preparation

Details
TypeSolution-IDContentsDetailsLabelSolvent system
micelle10.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O15N-labeled single-cysteine C317 alpha7 TMD+ICD for titration NMR experiments by ivermectin. Additional mutations include C219A, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C317_195% H2O/5% D2O
micelle20.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 30 uM ivermectin, 0.1 % DMSO, 95% H2O/5% D2O15N-labeled single-cysteine C317 alpha7 TMD+ICD for titration NMR experiments by ivermectin. Additional mutations include C219A, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C317_295% H2O/5% D2O
micelle30.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 100 uM ivermectin, 0.3 % DMSO, 95% H2O/5% D2O15N-labeled single-cysteine C317 alpha7 TMD+ICD for titration NMR experiments by ivermectin. Additional mutations include C219A, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C317_395% H2O/5% D2O
micelle40.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 250 uM ivermectin, 0.55 % DMSO, 95% H2O/5% D2O15N-labeled single-cysteine C317 alpha7 TMD+ICD for titration NMR experiments by ivermectin. Additional mutations include C219A, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C317_495% H2O/5% D2O
micelle50.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.95 % DMSO, 95% H2O/5% D2O15N-labeled single-cysteine C317 alpha7 TMD+ICD for titration NMR experiments by ivermectin. Additional mutations include C219A, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C317_595% H2O/5% D2O
micelle60.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O15N-labeled single-cysteine C317 alpha7 TMD+ICD for 1D and STD NMR experiments (saturation of ivermectin peaks C1''H/C3H). Additional mutations include C219A, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C317_695% H2O/5% D2O
micelle70.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O15N-labeled single-cysteine C317 alpha7 TMD+ICD for 1D and STD NMR experiments (saturation of ivermectin peak C11H). Additional mutations include C219A, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C317_795% H2O/5% D2O
micelle80.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O15N-labeled single-cysteine C317 alpha7 TMD+ICD for 1D and STD NMR experiments (saturation of ivermectin peak C15H). Additional mutations include C219A, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C317_895% H2O/5% D2O
micelle90.20 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O15N-labeled single-cysteine C317 alpha7 TMD+ICD for 2D NOESY NMR experiments (mixing time: 120 and 200 ms). Additional mutations include C219A, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C317_995% H2O/5% D2O
micelle100.22 mM [U-15N] V311C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 220 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O15N-labeled, single-cysteine V311C-MTSL-labeled alpha7 TMD+ICD with 0- and 2.2-mM ascorbic acid for PRE NMR (0.22 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_V311C-MTSL_1095% H2O/5% D2O
micelle110.22 mM [U-15N] V311C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O15N-labeled, single-cysteine V311C-MTSL-labeled alpha7 TMD+ICD with 0- and 2.2-mM ascorbic acid for PRE NMR (0 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_V311C-MTSL_1195% H2O/5% D2O
micelle120.22 mM [U-15N] C335-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 220 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O15N-labeled, single-cysteine C335-MTSL-labeled alpha7 TMD+ICD with 0- and 2.2-mM ascorbic acid for PRE NMR (0.22 mM ivermectin). Additional mutations include C219A, C317S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C335-MTSL_1295% H2O/5% D2O
micelle130.22 mM [U-15N] C335-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O15N-labeled, single-cysteine C335-MTSL-labeled alpha7 TMD+ICD with 0- and 2.2-mM ascorbic acid for PRE NMR (0 mM ivermectin). Additional mutations include C219A, C317S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C335-MTSL_1395% H2O/5% D2O
micelle140.2 mM [U-15N] C342-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O15N-labeled, single-cysteine C342-MTSL-labeled alpha7 TMD+ICD with 0- and 2.0-mM ascorbic acid for PRE NMR (0.2 mM ivermectin). Additional mutations include C219A, C317S, C335S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C342-MTSL_1495% H2O/5% D2O
micelle150.2 % [U-15N] C342-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O15N-labeled, single-cysteine C342-MTSL-labeled alpha7 TMD+ICD with 0- and 2.0-mM ascorbic acid for PRE NMR (0 mM ivermectin). Additional mutations include C219A, C317S, C335S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C342-MTSL_1595% H2O/5% D2O
micelle160.2 mM [U-15N] S350C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O15N-labeled, single-cysteine S350C-MTSL-labeled alpha7 TMD+ICD with 0- and 2.0-mM ascorbic acid for PRE NMR (0.2 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_S350C-MTSL_1695% H2O/5% D2O
micelle170.2 mM [U-15N] S350C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O15N-labeled, single-cysteine S350C-MTSL-labeled alpha7 TMD+ICD with 0- and 2.0-mM ascorbic acid for PRE NMR (0 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_S350C-MTSL_1795% H2O/5% D2O
micelle180.2 mM [U-15N] C375-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O15N-labeled, single-cysteine C375-MTSL-labeled alpha7 TMD+ICD with 0- and 2.0-mM ascorbic acid for PRE NMR (0.2 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C385S, C390S, C427S, C435S, C443S, C449A, C460A. 15N-labeled, single-cysteine S350C-MTSL-labeled alpha7 TMD+ICD with 0- and 2.0-mM ascorbic acid for PRE NMR (0.2 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C375-MTSL_1895% H2O/5% D2O
micelle190.2 mM [U-15N] C375-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O15N-labeled, single-cysteine C375-MTSL-labeled alpha7 TMD+ICD with 0- and 2.0-mM ascorbic acid for PRE NMR (0 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C385S, C390S, C427S, C435S, C443S, C449A, C460A. 15N-labeled, single-cysteine S350C-MTSL-labeled alpha7 TMD+ICD with 0- and 2.0-mM ascorbic acid for PRE NMR (0.2 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_C375-MTSL_1995% H2O/5% D2O
micelle200.25 mM [U-15N] C390-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 250 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O15N-labeled, single-cysteine C390-MTSL-labeled alpha7 TMD+ICD with 0- and 2.5-mM ascorbic acid for PRE NMR (0.25 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C427S, C435S, C443S, C449A, C460A.15N_a7_C390-MTSL_2095% H2O/5% D2O
micelle210.25 mM [U-15N] C390-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O15N-labeled, single-cysteine C390-MTSL-labeled alpha7 TMD+ICD with 0- and 2.5-mM ascorbic acid for PRE NMR (0 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C427S, C435S, C443S, C449A, C460A.15N_a7_C390-MTSL_2195% H2O/5% D2O
micelle220.24 mM [U-15N] L415C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 240 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O15N-labeled, single-cysteine L415C-MTSL-labeled alpha7 TMD+ICD with 0- and 2.4-mM ascorbic acid for PRE NMR (0.24 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_L415C-MTSL_2295% H2O/5% D2O
micelle230.24 mM [U-15N] L415C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O15N-labeled, single-cysteine L415C-MTSL-labeled alpha7 TMD+ICD with 0- and 2.4-mM ascorbic acid for PRE NMR (0 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_a7_L415C-MTSL_2395% H2O/5% D2O
micelle240.2 mM [U-15N] C435-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 22 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O15N-labeled, single-cysteine C435-MTSL-labeled alpha7 TMD+ICD with 0- and 2.0-mM ascorbic acid for PRE NMR (0.2 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C390S, C427S, C443S, C449A, C460A.15N_a7_C435-MTSL_2495% H2O/5% D2O
micelle250.2 mM [U-15N] C435-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 22 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O15N-labeled, single-cysteine C435-MTSL-labeled alpha7 TMD+ICD with 0- and 2.0-mM ascorbic acid for PRE NMR (0 mM ivermectin). Additional mutations include C219A, C317S, C335S, C342S, C375S, C385S, C390S, C427S, C443S, C449A, C460A.15N_a7_C435-MTSL_2595% H2O/5% D2O
micelle260.22 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 30 uM ivermectin, 30 uM PNU, 0.2 % DMSO, 95% H2O/5% D2O15N-, 13C-labeled single-cysteine C317 alpha7 TMD+ICD (30 uM ivermectin and 30 uM PNU). Additional mutations include C219A, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_13C_a7_C317_2695% H2O/5% D2O
micelle270.22 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O15N-, 13C-labeled single-cysteine C317 alpha7 TMD+ICD (30 uM ivermectin and 30 uM PNU). Additional mutations include C219A, C335S, C342S, C375S, C385S, C390S, C427S, C435S, C443S, C449A, C460A.15N_13C_a7_C317_2795% H2O/5% D2O
Sample
Conc. (mg/ml)ComponentIsotopic labelingSolution-ID
0.25 mMalpha7nAChR C317 TMD+ICD[U-15N]1
5 mMsodium acetatenatural abundance1
35 mMLDAOnatural abundance1
25 mMsodium chloridenatural abundance1
5 %D2Onatural abundance1
20 uMDSSnatural abundance1
0.25 mMalpha7nAChR C317 TMD+ICD[U-15N]2
5 mMsodium acetatenatural abundance2
35 mMLDAOnatural abundance2
25 mMsodium chloridenatural abundance2
5 %D2Onatural abundance2
20 uMDSSnatural abundance2
30 uMivermectinnatural abundance2
0.1 %DMSOnatural abundance2
0.25 mMalpha7nAChR C317 TMD+ICD[U-15N]3
5 mMsodium acetatenatural abundance3
35 mMLDAOnatural abundance3
25 mMsodium chloridenatural abundance3
5 %D2Onatural abundance3
20 uMDSSnatural abundance3
100 uMivermectinnatural abundance3
0.3 %DMSOnatural abundance3
0.25 mMalpha7nAChR C317 TMD+ICD[U-15N]4
5 mMsodium acetatenatural abundance4
35 mMLDAOnatural abundance4
25 mMsodium chloridenatural abundance4
5 %D2Onatural abundance4
20 uMDSSnatural abundance4
250 uMivermectinnatural abundance4
0.55 %DMSOnatural abundance4
0.25 mMalpha7nAChR C317 TMD+ICD[U-15N]5
5 mMsodium acetatenatural abundance5
35 mMLDAOnatural abundance5
25 mMsodium chloridenatural abundance5
5 %D2Onatural abundance5
20 uMDSSnatural abundance5
500 uMivermectinnatural abundance5
0.95 %DMSOnatural abundance5
0.25 mMalpha7nAChR C317 TMD+ICD[U-15N]6
5 mMsodium acetatenatural abundance6
35 mMLDAOnatural abundance6
25 mMsodium chloridenatural abundance6
5 %D2Onatural abundance6
20 uMDSSnatural abundance6
500 uMivermectinnatural abundance6
0.8 %DMSOnatural abundance6
0.25 mMalpha7nAChR C317 TMD+ICD[U-15N]7
5 mMsodium acetatenatural abundance7
35 mMLDAOnatural abundance7
25 mMsodium chloridenatural abundance7
5 %D2Onatural abundance7
20 uMDSSnatural abundance7
500 uMivermectinnatural abundance7
0.8 %DMSOnatural abundance7
0.25 mMalpha7nAChR C317 TMD+ICD[U-15N]8
5 mMsodium acetatenatural abundance8
35 mMLDAOnatural abundance8
25 mMsodium chloridenatural abundance8
5 %D2Onatural abundance8
20 uMDSSnatural abundance8
500 uMivermectinnatural abundance8
0.8 %DMSOnatural abundance8
0.20 mMalpha7nAChR C317 TMD+ICD[U-15N]9
5 mMsodium acetatenatural abundance9
35 mMLDAOnatural abundance9
25 mMsodium chloridenatural abundance9
5 %D2Onatural abundance9
20 uMDSSnatural abundance9
500 uMivermectinnatural abundance9
0.8 %DMSOnatural abundance9
0.22 mMV311C-MTSL alpha7nAChR TMD+ICD[U-15N]10
5 mMsodium acetatenatural abundance10
35 mMLDAOnatural abundance10
25 mMsodium chloridenatural abundance10
5 %D2Onatural abundance10
20 uMDSSnatural abundance10
220 uMivermectinnatural abundance10
0.4 %DMSOnatural abundance10
0.22 mMV311C-MTSL alpha7nAChR TMD+ICD[U-15N]11
5 mMsodium acetatenatural abundance11
35 mMLDAOnatural abundance11
25 mMsodium chloridenatural abundance11
5 %D2Onatural abundance11
20 uMDSSnatural abundance11
0.22 mMC335-MTSL alpha7nAChR TMD+ICD[U-15N]12
5 mMsodium acetatenatural abundance12
26 mMLDAOnatural abundance12
25 mMsodium chloridenatural abundance12
5 %D2Onatural abundance12
20 uMDSSnatural abundance12
220 uMivermectinnatural abundance12
0.4 %DMSOnatural abundance12
0.22 mMC335-MTSL alpha7nAChR TMD+ICD[U-15N]13
5 mMsodium acetatenatural abundance13
26 mMLDAOnatural abundance13
25 mMsodium chloridenatural abundance13
5 %D2Onatural abundance13
20 uMDSSnatural abundance13
0.2 mMC342-MTSL alpha7nAChR TMD+ICD[U-15N]14
5 mMsodium acetatenatural abundance14
26 mMLDAOnatural abundance14
25 mMsodium chloridenatural abundance14
5 %D2Onatural abundance14
20 uMDSSnatural abundance14
200 uMivermectinnatural abundance14
0.4 %DMSOnatural abundance14
0.2 %C342-MTSL alpha7nAChR TMD+ICD[U-15N]15
5 mMsodium acetatenatural abundance15
26 mMLDAOnatural abundance15
25 mMsodium chloridenatural abundance15
5 %D2Onatural abundance15
20 uMDSSnatural abundance15
0.2 mMS350C-MTSL alpha7nAChR TMD+ICD[U-15N]16
5 mMsodium acetatenatural abundance16
44 mMLDAOnatural abundance16
25 mMsodium chloridenatural abundance16
5 %D2Onatural abundance16
20 uMDSSnatural abundance16
200 uMivermectinnatural abundance16
0.4 %DMSOnatural abundance16
0.2 mMS350C-MTSL alpha7nAChR TMD+ICD[U-15N]17
5 mMsodium acetatenatural abundance17
44 mMLDAOnatural abundance17
25 mMsodium chloridenatural abundance17
5 %D2Onatural abundance17
20 uMDSSnatural abundance17
0.2 mMC375-MTSL alpha7nAChR TMD+ICD[U-15N]18
5 mMsodium acetatenatural abundance18
35 mMLDAOnatural abundance18
25 mMsodium chloridenatural abundance18
5 %D2Onatural abundance18
20 uMDSSnatural abundance18
200 uMivermectinnatural abundance18
0.4 %DMSOnatural abundance18
0.2 mMC375-MTSL alpha7nAChR TMD+ICD[U-15N]19
5 mMsodium acetatenatural abundance19
35 mMLDAOnatural abundance19
25 mMsodium chloridenatural abundance19
5 %D2Onatural abundance19
20 uMDSSnatural abundance19
0.25 mMC390-MTSL alpha7nAChR TMD+ICD[U-15N]20
5 mMsodium acetatenatural abundance20
44 mMLDAOnatural abundance20
25 mMsodium chloridenatural abundance20
5 %D2Onatural abundance20
20 uMDSSnatural abundance20
250 uMivermectinnatural abundance20
0.4 %DMSOnatural abundance20
0.25 mMC390-MTSL alpha7nAChR TMD+ICD[U-15N]21
5 mMsodium acetatenatural abundance21
44 mMLDAOnatural abundance21
25 mMsodium chloridenatural abundance21
5 %D2Onatural abundance21
20 uMDSSnatural abundance21
0.24 mML415C-MTSL alpha7nAChR TMD+ICD[U-15N]22
5 mMsodium acetatenatural abundance22
35 mMLDAOnatural abundance22
25 mMsodium chloridenatural abundance22
5 %D2Onatural abundance22
20 uMDSSnatural abundance22
240 uMivermectinnatural abundance22
0.4 %DMSOnatural abundance22
0.24 mML415C-MTSL alpha7nAChR TMD+ICD[U-15N]23
5 mMsodium acetatenatural abundance23
35 mMLDAOnatural abundance23
25 mMsodium chloridenatural abundance23
5 %D2Onatural abundance23
20 uMDSSnatural abundance23
0.2 mMC435-MTSL alpha7nAChR TMD+ICD[U-15N]24
5 mMsodium acetatenatural abundance24
22 mMLDAOnatural abundance24
25 mMsodium chloridenatural abundance24
5 %D2Onatural abundance24
20 uMDSSnatural abundance24
200 uMivermectinnatural abundance24
0.4 %DMSOnatural abundance24
0.2 mMC435-MTSL alpha7nAChR TMD+ICD[U-15N]25
5 mMsodium acetatenatural abundance25
22 mMLDAOnatural abundance25
25 mMsodium chloridenatural abundance25
5 %D2Onatural abundance25
20 uMDSSnatural abundance25
0.22 mMalpha7nAChR C317 TMD+ICD[U-13C; U-15N]26
5 mMsodium acetatenatural abundance26
44 mMLDAOnatural abundance26
25 mMsodium chloridenatural abundance26
5 %D2Onatural abundance26
20 uMDSSnatural abundance26
30 uMivermectinnatural abundance26
30 uMPNUnatural abundance26
0.2 %DMSOnatural abundance26
0.22 mMalpha7nAChR C317 TMD+ICD[U-13C; U-15N]27
5 mMsodium acetatenatural abundance27
44 mMLDAOnatural abundance27
25 mMsodium chloridenatural abundance27
5 %D2Onatural abundance27
20 uMDSSnatural abundance27
Sample conditionsIonic strength: 25 mM / Label: condition_s1 / pH: 4.7 / Pressure: 1 atm / Temperature: 318 K

-
NMR measurement

NMR spectrometerType: Bruker AVANCE II / Manufacturer: Bruker / Model: AVANCE II / Field strength: 800 MHz

-
Processing

NMR software
NameVersionDeveloperClassification
TopSpin3.2Bruker Biospincollection
NMRPipe10.9Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Baxprocessing
Sparky3.19Goddarddata analysis
NMRFAM-SPARKY1.47Lee, Tonelli and Markleydata analysis
CS-ROSETTA3.17Shen, Vernon, Baker and Baxstructure calculation
Rosetta3.7Leaver-Fay, Tyka, Lewis, Lange, Thompson, Jacak, Kaufman, Renfrew, Smith, Sheffler, Davis, Cooper, Treuille, Mandell, Richter, Ban, Fleishman, Corn, Kim, Lyskov, Berrondo, Mentzer, Popovic, Havranek, Karanicolas, Das, Meiler, Kortemme, Gray, Kuhlman, Baker, and Bradleystructure calculation
Rosetta3.7Leaver-Fay, Tyka, Lewis, Lange, Thompson, Jacak, Kaufman, Renfrew, Smith, Sheffler, Davis, Cooper, Treuille, Mandell, Richter, Ban, Fleishman, Corn, Kim, Lyskov, Berrondo, Mentzer, Popovic, Havranek, Karanicolas, Das, Meiler, Kortemme, Gray, Kuhlman, Baker, and Bradleyrefinement
MolProbityRichardsonrefinement
Refinement
MethodSoftware ordinal
na7
na8
NMR representativeSelection criteria: lowest energy
NMR ensembleConformer selection criteria: structures with the lowest energy
Conformers calculated total number: 1000 / Conformers submitted total number: 15

+
About Yorodumi

-
News

-
Feb 9, 2022. New format data for meta-information of EMDB entries

New format data for meta-information of EMDB entries

  • Version 3 of the EMDB header file is now the official format.
  • The previous official version 1.9 will be removed from the archive.

Related info.:EMDB header

External links:wwPDB to switch to version 3 of the EMDB data model

-
Aug 12, 2020. Covid-19 info

Covid-19 info

URL: https://pdbj.org/emnavi/covid19.php

New page: Covid-19 featured information page in EM Navigator.

Related info.:Covid-19 info / Mar 5, 2020. Novel coronavirus structure data

+
Mar 5, 2020. Novel coronavirus structure data

Novel coronavirus structure data

Related info.:Yorodumi Speices / Aug 12, 2020. Covid-19 info

External links:COVID-19 featured content - PDBj / Molecule of the Month (242)：Coronavirus Proteases

+
Jan 31, 2019. EMDB accession codes are about to change! (news from PDBe EMDB page)

EMDB accession codes are about to change! (news from PDBe EMDB page)

  • The allocation of 4 digits for EMDB accession codes will soon come to an end. Whilst these codes will remain in use, new EMDB accession codes will include an additional digit and will expand incrementally as the available range of codes is exhausted. The current 4-digit format prefixed with “EMD-” (i.e. EMD-XXXX) will advance to a 5-digit format (i.e. EMD-XXXXX), and so on. It is currently estimated that the 4-digit codes will be depleted around Spring 2019, at which point the 5-digit format will come into force.
  • The EM Navigator/Yorodumi systems omit the EMD- prefix.

Related info.:Q: What is EMD? / ID/Accession-code notation in Yorodumi/EM Navigator

External links:EMDB Accession Codes are Changing Soon! / Contact to PDBj

+
Jul 12, 2017. Major update of PDB

Major update of PDB

  • wwPDB released updated PDB data conforming to the new PDBx/mmCIF dictionary.
  • This is a major update changing the version number from 4 to 5, and with Remediation, in which all the entries are updated.
  • In this update, many items about electron microscopy experimental information are reorganized (e.g. em_software).
  • Now, EM Navigator and Yorodumi are based on the updated data.

External links:wwPDB Remediation / Enriched Model Files Conforming to OneDep Data Standards Now Available in the PDB FTP Archive

-
Yorodumi

Thousand views of thousand structures

  • Yorodumi is a browser for structure data from EMDB, PDB, SASBDB, etc.
  • This page is also the successor to EM Navigator detail page, and also detail information page/front-end page for Omokage search.
  • The word "yorodu" (or yorozu) is an old Japanese word meaning "ten thousand". "mi" (miru) is to see.

Related info.:EMDB / PDB / SASBDB / Comparison of 3 databanks / Yorodumi Search / Aug 31, 2016. New EM Navigator & Yorodumi / Yorodumi Papers / Jmol/JSmol / Function and homology information / Changes in new EM Navigator and Yorodumi

Read more